抗糖尿病肽类药物研究进展  

Research Advances of Peptides Counteracting Diabetes Mellitus

作　　者：严国文[1] 李谦[1] 何书英[1] 朱杰[1] 吴梧桐[1] 

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京210009

出　　处：《药物生物技术》2012年第3期270-273,共4页Pharmaceutical Biotechnology

基　　金：中央高校基本科研业务费专项资金资助(No.2011042)

摘　　要：糖尿病是以胰岛素相对或绝对不足为特征的代谢性疾病,严重危害人类健康,传统抗糖尿病药物各有缺点,从而催生了抗糖尿病肽类药物的面世。常见于文献报道的抗糖尿病肽有胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)受体激动剂、基于胰淀素开发的抗糖尿病肽、动植物来源的抗糖尿病肽和抗糖尿病寡肽,其中前者又包括GLP-1衍生物和GLP-1类似物。该文对它们各自的优缺点,研发思路和药理效应作了综述。Diabetes Mellitus （DM） is a metabolic syndrome characterized by absolutely or comparatively insufficient insulin. DM is substantially hazardous to human health. The defects of traditional antihyperglycemic drugs have accelerated the development of peptide-based antidiabetic agents. Such agents frequently reported in published works are Glucagon-like peptide-1 （ GLP-1 ） receptor agonists that include GLP-1 derivatives and GLP-1 analogs, amylin-based antidiabetic peptides （ABAPs） , animals or plants-derived antidiabetic peptides （APDAPs） and antidiabetic oligopeptides （ADOPs）. This review summarizes the existing knowledge concerning advantages, drawbacks, developing thoughts and pharmaceutical effects of the four kinds of pcptides, respectively.

关 键 词：糖尿病 降血糖药物 肽 胰高血糖素样肽-1 艾塞那肽 胰淀素 抗糖尿病寡肽 

分 类 号：R977.15[医药卫生—药品]